• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol. Diagnostic Accuracy of an Automated Chemiluminescent Immunoassay for anti-SARS-CoV-2 IgM and IgG Antibodies: An Italian Experience

tetano

Editor, Senior Moderator
J Med Virol. 2020 Apr 24.
doi: 10.1002/jmv.25932. Online ahead of print.
Diagnostic Accuracy of an Automated Chemiluminescent Immunoassay for anti-SARS-CoV-2 IgM and IgG Antibodies: An Italian Experience


M Infantino[SUP] 1 [/SUP], V Grossi[SUP] 1 [/SUP], B Lari[SUP] 1 [/SUP], R Bambi[SUP] 1 [/SUP], A Perri[SUP] 1 [/SUP], M Manneschi[SUP] 1 [/SUP], G Terenzi[SUP] 1 [/SUP], I Liotti[SUP] 1 [/SUP], G Ciotta[SUP] 1 [/SUP], C Taddei[SUP] 1 [/SUP], M Benucci[SUP] 2 [/SUP], P Casprini[SUP] 3 [/SUP], F Veneziani[SUP] 4 [/SUP], S Fabbri[SUP] 1 4 [/SUP], A Pompetti[SUP] 5 [/SUP], M Manfredi[SUP] 1 [/SUP]



Affiliations

Abstract

Background: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play.
Methods: Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab RT-PCR result.
Results: The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The ROC performance curves showed area under the curve (AUC) values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively.
Conclusions: iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics. This article is protected by copyright. All rights reserved.
 
Back
Top